By Priyanjana Pramanik, MSc. New research reveals that patients receiving heparin therapy were diagnosed with Alzheimer's ...

Longeveron (NASDAQ: LGVN) , a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, will be represented at ...

A research team led by Associate Professor Hidetoshi Sakurai and Researcher Nana Takenaka-Ninagawa recently demonstrated the ...

As the travel industry struggles to reduce its environmental impact, here's how cruise lines are working towards sustainable ...

To register for the event, please contact your UBS representative. The Longeveron investor presentation is available at the “Events & Presentations” section of the Company’s website. About Longeveron ...

NDAQ:BCLI) BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn® Trial at the 2024 Maxim Healthcare ...

A cross-disciplinary team, led by the University of Glasgow, alongside the Universities of Nottingham and Strathclyde, will use pioneering technology ...

A cross-disciplinary team, led by the University of Glasgow, will use pioneering technology to manufacture human stem cells ...

USA: A recent study published in Nature Biotechnology has demonstrated the feasibility of using encapsulated stem ...

What advancements can be made to improve the efficiency and accuracy of studying worldwide diseases? This is what a recent study published in Nature Commun | Technology ...

The U.S. Court of Appeals for the Ninth Circuit on Friday reversed the district court’s judgment in United States v. California Stem Cell ...

Evidence from recent phase 3 trials has changed the treatment of diffuse B cell lymphoma - Theresa Lowry-Lehren reports on ...